Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China

Akeso's ivonescimab antibody drug shows a smaller clinical benefit with extended follow-up in Chinese patients, indicating potential challenges in demonstrating long-term efficacy.

This Wire brief sits within Fusion42's coverage of Biotech.